Access cutting-edge prostate carcinoma treatment through this phase 2 clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Los Angeles location
Preparing your pre-screening questions…
Access prostate carcinoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate carcinoma treatment provided free
Check if you qualify for this prostate carcinoma clinical trial in Los Angeles, CA
No-Cost Study Care
Local to Los Angeles
Convenient for CA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells. This allows for visualization of PSMA-expressing cells upon imaging. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes x-rays that track the body from the outside. CT images provide an exact outline of the organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic information obtained from the PET scan. Metabolic information means how much of the injected tracer is taken up by inflammatory tissue. Flotufolastat F 18 PET/CT imaging may be an effective and less invasive way to detect residual or recurrent disease in prostate cancer patients, compared to other methods.
Sponsor: Jonsson Comprehensive Cancer Center
Yes, this clinical trial (NCT07185165) has an active research site in Los Angeles, CA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for prostate carcinoma treatment options in Los Angeles, CA, this clinical trial (NCT07185165) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced prostate carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all prostate carcinoma clinical trials near you to find additional studies recruiting in your area.
See all prostate cancer clinical trials recruiting in Los Angeles — not just this study.
Browse Prostate Cancer Trials in Los Angeles →